RT Journal Article
T1 Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
A1 Garcia-Gutierrez, Valentin
A1 Luna, Alejandro
A1 Alonso-Dominguez, Juan M
A1 Estrada, Natalia
A1 Boque, Concepcion
A1 Xicoy, Blanca
A1 Giraldo, Pilar
A1 Angona, Anna
A1 Alvarez-Larran, Alberto
A1 Sanchez-Guijo, Fermin
A1 Ramirez, Maria Jose
A1 Mora, Elvira
A1 Velez, Patricia
A1 Rosell, Ana
A1 Colorado-Araujo, Mercedes
A1 Cuevas, Beatriz
A1 Sagües, Miguel
A1 Cortes, Montserrat
A1 Perez-Encinas, Manuel
A1 Casado Montero, Luis Felipe
A1 Moreno-Vega, Melania
A1 Serrano, Luis
A1 Gomez, Valle
A1 Garcia-Hernandez, Carmen
A1 Lakhwani, Sunil
A1 Paz-Coll, Antonio
A1 de-Paz, Raquel
A1 Suarez-Varela, Sara
A1 Fernandez-Ruiz, Andres
A1 Perez-Lopez, Raul
A1 Ortiz-Fernandez, Almudena
A1 Jimenez-Velasco, Antonio
A1 Steegmann-Olmedillas, Juan Luis
A1 Hernandez-Boluda, Juan Carlos
K1 Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
K1 Protein Kinase Inhibitors
K1 Pyrazoles
K1 Treatment Outcome
K1 Young Adult
AB Despite the excellent overall survival (OS) of chronic myeloid leukemia (CML) patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) due to resistance or intolerance. Intolerant patients are usually managed successfully with alternative second-generation tyrosine-kinase inhibitors (2GTKIs). However, more than half of the patients will eventually discontinue second-line treatment due to loss of response or toxicity. Ponatinib is an effective drug in the setting of resistance to 2GTKIs, however with life-threatening side effects and varying responses.
PB Nature Publishing Group
YR 2021
FD 2021-02-09
LK http://hdl.handle.net/10668/17137
UL http://hdl.handle.net/10668/17137
LA en
NO Garcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, Estrada N, Boque C, Xicoy B, et al. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer J. 2021 Feb 9;11(2):16
DS RISalud
RD Apr 6, 2025